VTRS
Viatris Inc.Healthcare · $20.8B market cap
Verdict
Share price
$17.60
close of Oct 3, 2026
Fair value
$7.89
Sticker Price
Payback Price
$3.16
buy price
VTRS is Overpriced: at $17.60 it trades 123% above its fair value of $7.89. Its buy price (Payback Price) is $3.16, 82% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.
How we valued it
Free Cash Flow Growth. Free cash flow is growing faster than reported earnings, so we project free cash flow 10 years ahead instead.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow VTRS
Get notified when it reaches its buy price of $3.16. Free.
Create a free accountSuperinvestors
2 of the investors we track hold VTRS. In Q1 2026, 1 added. Who we track
David Einhorn
Greenlight Capital · as of Q4 2023
$36.3M
3,355,770 shares
Bill Miller
Miller Value Partners · as of Q2 2026
$11.6M
733,164 shares
Moves in Q1 2026
Added: Bill Miller
Insider activity
Since Jun 25, 2026: no open-market purchases, 1 sale worth $810K and 7 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
Enrietti Andrew
See Remarks · 2026-08-15
Option exercise
998.364 shares
Enrietti Andrew
See Remarks · 2026-08-15
Tax withholding
$177K
Enrietti Andrew
See Remarks · 2026-08-15
Tax withholding
$7K
Enrietti Andrew
See Remarks · 2026-08-15
Option exercise
999 shares
Enrietti Andrew
See Remarks · 2026-08-15
Option exercise
25,134 shares
Show all 7 other filingsShow fewer
Groothuis Leo Frans
director · 2026-06-30
Award
2,756 shares
SIMMONS DAVID S
director · 2026-06-30
Award
2,362 shares
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works